BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jharap B, Seinen ML, de Boer NK, van Ginkel JR, Linskens RK, Kneppelhout JC, Mulder CJ, van Bodegraven AA. Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts. Inflamm Bowel Dis 2010;16:1541-9. [PMID: 20155846 DOI: 10.1002/ibd.21221] [Cited by in Crossref: 124] [Cited by in F6Publishing: 116] [Article Influence: 10.3] [Reference Citation Analysis]
Number Citing Articles
1 de Boer NKH, Peyrin-biroulet L, Jharap B, Sanderson JD, Meijer B, Atreya I, Barclay ML, Colombel J, Lopez A, Beaugerie L, Marinaki AM, van Bodegraven AA, Neurath MF. Thiopurines in Inflammatory Bowel Disease: New Findings and Perspectives. Journal of Crohn's and Colitis 2018;12:610-20. [DOI: 10.1093/ecco-jcc/jjx181] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
2 van Asseldonk DP, Simsek M, de Boer NKH, Jharap B, Bloemena E, den Hartog G, Westerveld DB, Becx MC, Russel MG, Lissenberg-witte BI, van Nieuwkerk CM, Mulder CJJ, Verheij J, van Bodegraven AA. Limited relevance and progression of histological alterations in the liver during thioguanine therapy in inflammatory bowel disease patients. Scandinavian Journal of Gastroenterology 2019;54:753-60. [DOI: 10.1080/00365521.2019.1629006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
3 Peyrin-Biroulet L, Oussalah A, Roblin X, Sparrow MP. The use of azathioprine in Crohn’s disease during pregnancy and in the post-operative setting: a worldwide survey of experts. Aliment Pharmacol Ther. 2011;33:707-713. [PMID: 21251032 DOI: 10.1111/j.1365-2036.2011.04577.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
4 Seinen ML, van Nieuw Amerongen GP, de Boer NK, Mulder CJ, van Bezu J, van Bodegraven AA. Rac1 as a Potential Pharmacodynamic Biomarker for Thiopurine Therapy in Inflammatory Bowel Disease. Ther Drug Monit 2016;38:621-7. [PMID: 27465973 DOI: 10.1097/FTD.0000000000000326] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
5 Hoentjen F, Seinen ML, Hanauer SB, de Boer NK, Rubin DT, Bouma G, Harrell LE, van Bodegraven AA. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:363-369. [PMID: 22605661 DOI: 10.1002/ibd.23021] [Cited by in Crossref: 72] [Cited by in F6Publishing: 62] [Article Influence: 8.0] [Reference Citation Analysis]
6 van Gennep S, de Boer NK, D'Haens GR, Löwenberg M. Thiopurine Treatment in Ulcerative Colitis: A Critical Review of the Evidence for Current Clinical Practice. Inflamm Bowel Dis 2017;24:67-77. [PMID: 29272488 DOI: 10.1093/ibd/izx025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
7 Beringer A, Citterio-Quentin A, Otero RO, Gustin C, Clarke R, Salvi JP, Boulieu R. Determination of inosine 5'-monophosphate dehydrogenase activity in red blood cells of thiopurine-treated patients using HPLC. J Chromatogr B Analyt Technol Biomed Life Sci 2017;1044-1045:194-9. [PMID: 28110955 DOI: 10.1016/j.jchromb.2017.01.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
8 Kopylov U, Amre D, Theoret Y, Deslandres C, Seidman EG. Thiopurine metabolite ratios for monitoring therapy in pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2014;59:511-5. [PMID: 24918978 DOI: 10.1097/MPG.0000000000000455] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 2.1] [Reference Citation Analysis]
9 Fei X, Shu Q, Zhu H, Hua B, Wang S, Guo L, Fang Y, Ge W. NUDT15 R139C Variants Increase the Risk of Azathioprine-Induced Leukopenia in Chinese Autoimmune Patients. Front Pharmacol 2018;9:460. [PMID: 29867468 DOI: 10.3389/fphar.2018.00460] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
10 van Gerven NM, de Boer YS, Mulder CJ, van Nieuwkerk CM, Bouma G. Auto immune hepatitis. World J Gastroenterol 2016; 22(19): 4651-4661 [PMID: 27217697 DOI: 10.3748/wjg.v22.i19.4651] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
11 Egmond R, Chin P, Zhang M, Sies CW, Barclay ML. High TPMT enzyme activity does not explain drug resistance due to preferential 6-methylmercaptopurine production in patients on thiopurine treatment. Aliment Pharmacol Ther 2012;35:1181-9. [DOI: 10.1111/j.1365-2036.2012.05084.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 4.3] [Reference Citation Analysis]
12 Wall GC, Muktar H, Effken C, Mahajan PB. Addition of Allopurinol for Altering Thiopurine Metabolism to Optimize Therapy in Patients with Inflammatory Bowel Disease. Pharmacotherapy 2018;38:259-70. [PMID: 29197117 DOI: 10.1002/phar.2067] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
13 Stournaras E, Qian W, Pappas A, Hong YY, Shawky R, Raine T, Parkes M; UK IBD BioResource Investigators., UK IBD Bioresource Investigators. Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn's disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource. Gut 2021;70:677-86. [PMID: 33004550 DOI: 10.1136/gutjnl-2019-320185] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
14 Meijer B, Mulder CJ, Peters GJ, van Bodegraven AA, de Boer NK. Efficacy of thioguanine treatment in inflammatory bowel disease: A systematic review. World J Gastroenterol 2016; 22(40): 9012-9021 [PMID: 27833392 DOI: 10.3748/wjg.v22.i40.9012] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
15 Seinen ML, Ponsioen CY, de Boer NK, Oldenburg B, Bouma G, Mulder CJ, van Bodegraven AA. Sustained clinical benefit and tolerability of methotrexate monotherapy after thiopurine therapy in patients with Crohn's disease. Clin Gastroenterol Hepatol 2013;11:667-72. [PMID: 23333660 DOI: 10.1016/j.cgh.2012.12.026] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
16 Gao X, Zhang FB, Ding L, Liu H, Wang XD, Chen BL, Bi HC, Xiao YL, Zhao LZ, Chen MH. The potential influence of 5-aminosalicylic acid on the induction of myelotoxicity during thiopurine therapy in inflammatory bowel disease patients. Eur J Gastroenterol Hepatol. 2012;24:958-964. [PMID: 22664938 DOI: 10.1097/meg.0b013e3283545ae3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 13] [Article Influence: 3.1] [Reference Citation Analysis]
17 Tran-Minh ML, Sousa P, Maillet M, Allez M, Gornet JM. Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease. World J Hepatol 2017; 9(13): 613-626 [PMID: 28539989 DOI: 10.4254/wjh.v9.i13.613] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
18 Lamb CA, Saifuddin A, Powell N, Rieder F. The Future of Precision Medicine to Predict Outcomes and Control Tissue Remodeling in Inflammatory Bowel Disease. Gastroenterology 2022;162:1525-42. [PMID: 34995532 DOI: 10.1053/j.gastro.2021.09.077] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Jharap B, de Boer N, Vos R, Smid K, Zwiers A, Peters G, Mulder C, Wilhelm A, van Bodegraven A. Biotransformation of 6-thioguanine in inflammatory bowel disease patients: a comparison of oral and intravenous administration of 6-thioguanine. Br J Pharmacol 2011;163:722-31. [PMID: 21323897 DOI: 10.1111/j.1476-5381.2011.01265.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
20 Simsek M, Deben DS, Horjus CS, Bénard MV, Lissenberg-Witte BI, Buiter HJC, van Luin M, Seinen ML, Mulder CJJ, Wong DR, de Boer NKH, van Bodegraven AA. Sustained effectiveness, safety and therapeutic drug monitoring of tioguanine in a cohort of 274 IBD patients intolerant for conventional therapies. Aliment Pharmacol Ther 2019;50:54-65. [PMID: 31094013 DOI: 10.1111/apt.15280] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
21 Iizuka M, Etou T, Shimodaira Y, Hatakeyama T, Sagara S. Cytapheresis re-induces high-rate steroid-free remission in patients with steroid-dependent and steroid-refractory ulcerative colitis. World J Gastroenterol 2021; 27(12): 1194-1212 [PMID: 33828394 DOI: 10.3748/wjg.v27.i12.1194] [Reference Citation Analysis]
22 Konidari A, Anagnostopoulos A, Bonnett LJ, Pirmohamed M, El-Matary W. Thiopurine monitoring in children with inflammatory bowel disease: a systematic review. Br J Clin Pharmacol 2014;78:467-76. [PMID: 24592889 DOI: 10.1111/bcp.12365] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
23 Seinen ML, van Asseldonk DP, de Boer NK, Bouma G, van Nieuwkerk CM, Mulder CJ, Bloemena E, van Bodegraven AA. Nodular Regenerative Hyperplasia of the Liver in Patients with IBD Treated with Allopurinol–Thiopurine Combination Therapy: . Inflammatory Bowel Diseases 2017;23:448-52. [DOI: 10.1097/mib.0000000000001036] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
24 González-Lama Y, Gisbert JP. Monitoring thiopurine metabolites in inflammatory bowel disease. Frontline Gastroenterol 2016;7:301-7. [PMID: 28839871 DOI: 10.1136/flgastro-2015-100681] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
25 Derijks LJJ, Wong DR, Hommes DW, van Bodegraven AA. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease. Clin Pharmacokinet 2018;57:1075-106. [PMID: 29512050 DOI: 10.1007/s40262-018-0639-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
26 Li T, Qiu Y, Li X, Zhuang X, Huang S, Li M, Feng R, Chen B, He Y, Zeng Z, Chen M, Zhang S. Thalidomide Combined With Azathioprine as Induction and Maintenance Therapy for Azathioprine-Refractory Crohn's Disease Patients. Front Med (Lausanne) 2020;7:557986. [PMID: 33240902 DOI: 10.3389/fmed.2020.557986] [Reference Citation Analysis]
27 Seinen ML, van Asseldonk DP, de Boer NK, Losekoot N, Smid K, Mulder CJ, Bouma G, Peters GJ, van Bodegraven AA. The effect of allopurinol and low-dose thiopurine combination therapy on the activity of three pivotal thiopurine metabolizing enzymes: results from a prospective pharmacological study. J Crohns Colitis. 2013;7:812-819. [PMID: 23317929 DOI: 10.1016/j.crohns.2012.12.006] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
28 Divers TJ. Azathioprine - a useful treatment for immune-mediated disorders in the horse?: Azathioprine as a treatment for immune-mediated disorders. Equine Veterinary Education 2010;22:501-2. [DOI: 10.1111/j.0957-7734.2010.00117.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
29 Seinen M, de Boer N, van Hoorn M, van Bodegraven A, Bouma G. Safe Use of Allopurinol and Low-dose Mercaptopurine Therapy During Pregnancy in an Ulcerative Colitis Patient: . Inflammatory Bowel Diseases 2013;19:E37. [DOI: 10.1002/ibd.22945] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
30 Moon W, Loftus EV. Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2016;43:863-883. [PMID: 26876431 DOI: 10.1111/apt.13559] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 8.8] [Reference Citation Analysis]
31 Meijer B, van Everdingen CK, Ramsoekh D, Stedman C, Frampton CMA, Mulder CJJ, Bouma G, de Boer NKH, Gearry RB. Transient elastography to assess liver stiffness in patients with inflammatory bowel disease. Dig Liver Dis 2018;50:48-53. [PMID: 29050997 DOI: 10.1016/j.dld.2017.09.128] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
32 Zhang F, Amat G, Tang Y, Chen R, Tian X, Hu W, Chen C, Shen S, Xie Y. NUDT15 Genetic Variants in Chinese Han, Uighur, Kirghiz, and Dai Nationalities. Front Pediatr 2022;10:832363. [DOI: 10.3389/fped.2022.832363] [Reference Citation Analysis]
33 Crouwel F, Buiter HJC, de Boer NK. Discontinuation rate of azathioprine. Liver Int 2020;40:3141. [PMID: 32627355 DOI: 10.1111/liv.14574] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Hindryckx P, Novak G. Can we move directly from 5-ASA to a biologic agent in ulcerative colitis? Best Pract Res Clin Gastroenterol 2018;32-33:9-15. [PMID: 30060944 DOI: 10.1016/j.bpg.2018.05.004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
35 Botros L, Szulcek R, Jansen SMA, Kurakula K, Goumans MTH, van Kuilenburg ABP, Vonk Noordegraaf A, de Man FS, Aman J, Bogaard HJ. The Effects of Mercaptopurine on Pulmonary Vascular Resistance and BMPR2 Expression in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 2020;202:296-9. [DOI: 10.1164/rccm.202003-0473le] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
36 Luber RP, Honap S, Cunningham G, Irving PM. Can We Predict the Toxicity and Response to Thiopurines in Inflammatory Bowel Diseases? Front Med (Lausanne) 2019;6:279. [PMID: 31850357 DOI: 10.3389/fmed.2019.00279] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
37 Lakatos PL, Kiss LS. Current status of thiopurine analogues in the treatment in Crohn's disease. World J Gastroenterol 2011; 17(39): 4372-4381 [PMID: 22110262 DOI: 10.3748/wjg.v17.i39.4372] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
38 Pudipeddi A, Kariyawasam V, Haifer C, Baraty B, Paramsothy S, Leong RW. Safety of drugs used for the treatment of Crohn’s disease. Expert Opinion on Drug Safety 2019;18:357-67. [DOI: 10.1080/14740338.2019.1612874] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
39 Meijer B, Seinen ML, van Egmond R, Bouma G, Mulder CJJ, van Bodegraven AA, de Boer NKH. Optimizing Thiopurine Therapy in Inflammatory Bowel Disease Among 2 Real-life Intercept Cohorts: Effect of Allopurinol Comedication? Inflamm Bowel Dis 2017;23:2011-7. [PMID: 28617756 DOI: 10.1097/MIB.0000000000001168] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 2.8] [Reference Citation Analysis]
40 Chouchana L, Narjoz C, Beaune P, Loriot M, Roblin X. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease: Review: pharmacogenetics of thiopurines in IBD. Alimentary Pharmacology & Therapeutics 2012;35:15-36. [DOI: 10.1111/j.1365-2036.2011.04905.x] [Cited by in Crossref: 111] [Cited by in F6Publishing: 97] [Article Influence: 10.1] [Reference Citation Analysis]
41 Qiu Y, Mao R, Zhang SH, Li MY, Guo J, Chen BL, He Y, Zeng ZR, Chen MH. Safety Profile of Thiopurines in Crohn Disease: Analysis of 893 Patient-Years Follow-Up in a Southern China Cohort. Medicine (Baltimore). 2015;94:e1513. [PMID: 26469893 DOI: 10.1097/md.0000000000001513] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
42 Mantzaris GJ. Thiopurines and Methotrexate Use in IBD Patients in a Biologic Era. Curr Treat Options Gastro 2017;15:84-104. [DOI: 10.1007/s11938-017-0128-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
43 Moreno-Rincón E, Benítez JM, Serrano-Ruiz FJ, Vázquez-Morón JM, Pallarés-Manrique H, Herrera-Justiniano JM, Leo-Carnerero E, Gómez-García MR, Cabello-Tapia MJ, Castro-Fernández M. Prognosis of Patients with Ulcerative Colitis in Sustained Remission After Thiopurines Withdrawal. Inflamm Bowel Dis. 2015;21:1564-1571. [PMID: 26070002 DOI: 10.1097/mib.0000000000000400] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
44 Wong DR, Coenen MJ, Derijks LJ, Vermeulen SH, van Marrewijk CJ, Klungel OH, Scheffer H, Franke B, Guchelaar HJ, de Jong DJ. Early prediction of thiopurine-induced hepatotoxicity in inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45:391-402. [PMID: 27943397 DOI: 10.1111/apt.13879] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
45 Broekman MMTJ, Coenen MJH, Wanten GJ, van Marrewijk CJ, Kievit W, Klungel OH, Verbeek ALM, Wong DR, Hooymans PM, Guchelaar HJ, Scheffer H, Derijks LJJ, Bouvy ML, de Jong DJ. Patients' beliefs about medicine are associated with early thiopurine discontinuation in patients with inflammatory bowel diseases. Eur J Gastroenterol Hepatol 2018;30:167-73. [PMID: 29120908 DOI: 10.1097/MEG.0000000000001025] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
46 Rispo A, Testa A, De Palma GD, Donetto S, Diaferia M, Musto D, Nardone O, Maione F, Caporaso N, Castiglione F. Different Profile of Efficacy of Thiopurines in Ulcerative Colitis and Crohn’s Disease. Inflamm Bowel Dis. 2015;21:2570-2575. [PMID: 26222340 DOI: 10.1097/mib.0000000000000538] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
47 Broekman MMTJ, Coenen MJH, van Marrewijk CJ, Wanten GJA, Wong DR, Verbeek ALM, Klungel OH, Hooymans PM, Guchelaar HJ, Scheffer H, Derijks LJJ, de Jong DJ; TOPIC Recruitment Team. More Dose-dependent Side Effects with Mercaptopurine over Azathioprine in IBD Treatment Due to Relatively Higher Dosing. Inflamm Bowel Dis 2017;23:1873-81. [PMID: 28644183 DOI: 10.1097/MIB.0000000000001163] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
48 Mishra R, Dhawan P, Srivastava AS, Singh AB. Inflammatory bowel disease: Therapeutic limitations and prospective of the stem cell therapy. World J Stem Cells 2020; 12(10): 1050-1066 [PMID: 33178391 DOI: 10.4252/wjsc.v12.i10.1050] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
49 Amin J, Huang B, Yoon J, Shih DQ. Update 2014: advances to optimize 6-mercaptopurine and azathioprine to reduce toxicity and improve efficacy in the management of IBD. Inflamm Bowel Dis. 2015;21:445-452. [PMID: 25248004 DOI: 10.1097/mib.0000000000000197] [Cited by in Crossref: 47] [Cited by in F6Publishing: 27] [Article Influence: 6.7] [Reference Citation Analysis]
50 de Hoogd S, Wong DR, de Vries DR, Harmsze AM. Severe pancytopenia and aspergillosis caused by thioguanine in a thiopurine S-methyltransferase deficient patient: a case report. Eur J Gastroenterol Hepatol 2019;31:1592-6. [PMID: 31464791 DOI: 10.1097/MEG.0000000000001504] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
51 Magro F, Santos-Antunes J, Vilas-Boas F, Rodrigues-Pinto E, Coelho R, Ribeiro OS, Lopes S, Macedo G. Crohn's disease outcome in patients under azathioprine: a tertiary referral center experience. J Crohns Colitis 2014;8:617-25. [PMID: 24332869 DOI: 10.1016/j.crohns.2013.11.020] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
52 Camus M, Seksik P, Bourrier A, Nion-Larmurier I, Sokol H, Baumer P, Beaugerie L, Cosnes J. Long-term outcome of patients with Crohn's disease who respond to azathioprine. Clin Gastroenterol Hepatol. 2013;11:389-394. [PMID: 23142207 DOI: 10.1016/j.cgh.2012.10.038] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 4.8] [Reference Citation Analysis]
53 Simsek M, Meijer B, van Bodegraven AA, de Boer NK, Mulder CJ. Finding hidden treasures in old drugs: the challenges and importance of licensing generics. Drug Discovery Today 2018;23:17-21. [DOI: 10.1016/j.drudis.2017.08.008] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
54 Ding L, Zhang FB, Liu H, Gao X, Bi HC, Huang L, Wang XD, Chen BL, Zhang Y, Lv C, Hu PJ, Huang M. Xanthine oxidase activity in thiopurine curative Chinese inflammatory bowel disease patients. Pharmacol Res Perspect 2021;9:e00764. [PMID: 33929082 DOI: 10.1002/prp2.764] [Reference Citation Analysis]
55 Sluiter RL, Van Marrewijk C, De Jong D, Scheffer H, Guchelaar HJ, Derijks L, Wong DR, Hooymans P, Vermeulen SH, Verbeek ALM, Franke B, Van der Wilt GJ, Kievit W, Coenen MJH. Genotype-Guided Thiopurine Dosing Does not Lead to Additional Costs in Patients With Inflammatory Bowel Disease. J Crohns Colitis 2019;13:838-45. [PMID: 30698675 DOI: 10.1093/ecco-jcc/jjz009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
56 Bayoumy AB, Mulder CJJ, Loganayagam A, Sanderson JD, Anderson S, Boekema PJ, Derijks LJJ, Ansari AR. Relationship Between Thiopurine S-Methyltransferase Genotype/Phenotype and 6-Thioguanine Nucleotide Levels in 316 Patients With Inflammatory Bowel Disease on 6-Thioguanine. Ther Drug Monit 2021;43:617-23. [PMID: 34521801 DOI: 10.1097/FTD.0000000000000869] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Mhanna M, Gharaibeh MG, Rashid M, Sharab A, Shehab M, Zihlif M. TPMT Genotype and Adverse Effects of Azathioprine among Jordanian Group. Curr Drug Metab 2019;20:889-97. [PMID: 31631819 DOI: 10.2174/1389200220666191021100953] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
58 Pugliese D, Aratari A, Festa S, Ferraro PM, Monterubbianesi R, Guidi L, Scribano ML, Papi C, Armuzzi A. Sustained Clinical Efficacy and Mucosal Healing of Thiopurine Maintenance Treatment in Ulcerative Colitis: A Real-Life Study. Gastroenterol Res Pract 2018;2018:4195968. [PMID: 30402090 DOI: 10.1155/2018/4195968] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
59 Dharmasiri S, Dewhurst H, Johnson H, Weaver S, McLaughlin S. Low dose thiopurine and allopurinol co-therapy results in significant cost savings at a district general hospital. Frontline Gastroenterol 2015;6:285-9. [PMID: 28839824 DOI: 10.1136/flgastro-2014-100504] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
60 Hoentjen F, Hanauer SB, de Boer NK, Rubin DT. Two brothers with skewed thiopurine metabolism in ulcerative colitis treated successfully with allopurinol and mercaptopurine dose reduction. Dig Dis Sci 2012;57:250-3. [PMID: 22147254 DOI: 10.1007/s10620-011-1999-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
61 Hoentjen F, Sakuraba A, Hanauer S. Update on the Management of Ulcerative Colitis. Curr Gastroenterol Rep 2011;13:475-85. [DOI: 10.1007/s11894-011-0216-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
62 Ince MN, Elliott DE. Effective Use of the Laboratory in the Management of Patients with Inflammatory Bowel Diseases. Gastroenterol Clin North Am 2019;48:237-58. [PMID: 31046973 DOI: 10.1016/j.gtc.2019.02.006] [Reference Citation Analysis]
63 Gargallo-Puyuelo CJ, Laredo V, Gomollón F. Thiopurines in Inflammatory Bowel Disease. How to Optimize Thiopurines in the Biologic Era? Front Med (Lausanne) 2021;8:681907. [PMID: 34336887 DOI: 10.3389/fmed.2021.681907] [Reference Citation Analysis]
64 Frei P, Biedermann L, Nielsen OH, Rogler G. Use of thiopurines in inflammatory bowel disease. World J Gastroenterol 2013; 19(7): 1040-1048 [PMID: 23467510 DOI: 10.3748/wjg.v19.i7.1040] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
65 Appell ML, Wagner A, Hindorf U. A skewed thiopurine metabolism is a common clinical phenomenon that can be successfully managed with a combination of low-dose azathioprine and allopurinol. Journal of Crohn's and Colitis 2013;7:510-3. [DOI: 10.1016/j.crohns.2012.10.016] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
66 Ding L, Zhang FB, Liu H, Gao X, Bi HC, Wang XD, Chen BL, Zhang Y, Zhao LZ, Zhong GP, Hu PJ, Chen MH, Huang M. Hypoxanthine guanine phosphoribosyltransferase activity is related to 6-thioguanine nucleotide concentrations and thiopurine-induced leukopenia in the treatment of inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:63-73. [PMID: 21381155 DOI: 10.1002/ibd.21676] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
67 Min MX, Weinberg DI, Mccabe RP. Allopurinol enhanced thiopurine treatment for inflammatory bowel disease: safety considerations and guidelines for use. J Clin Pharm Ther 2014;39:107-11. [DOI: 10.1111/jcpt.12125] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
68 Yeboah J, Sharma OP. Co-existence of Crohn's disease, sarcoidosis and malignant lymphomas. JRSM Short Rep. 2012;3:10. [PMID: 22393471 DOI: 10.1258/shorts.2011.011133] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
69 Shi HY, Chan FK, Leung WK, Li MK, Leung CM, Sze SF, Ching JY, Lo FH, Tsang SW, Shan EH, Mak LY, Lam BC, Hui AJ, Chow WH, Wong MT, Hung IF, Hui YT, Chan YK, Chan KH, Loo CK, Ng CK, Lao WC, Harbord M, Wu JC, Sung JJ, Ng SC. Low-dose azathioprine is effective in maintaining remission in steroid-dependent ulcerative colitis: results from a territory-wide Chinese population-based IBD registry. Therap Adv Gastroenterol. 2016;9:449-456. [PMID: 27366213 DOI: 10.1177/1756283x16643509] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
70 Kopylov U, Battat R, Benmassaoud A, Paradis-Surprenant L, Seidman EG. Hematologic indices as surrogate markers for monitoring thiopurine therapy in IBD. Dig Dis Sci. 2015;60:478-484. [PMID: 25236422 DOI: 10.1007/s10620-014-3362-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
71 Zhu X, Chao K, Li M, Xie W, Zheng H, Zhang JX, Hu PJ, Huang M, Gao X, Wang XD. Nucleoside diphosphate-linked moiety X-type motif 15 R139C genotypes impact 6-thioguanine nucleotide cut-off levels to predict thiopurine-induced leukopenia in Crohn’s disease patients. World J Gastroenterol 2019; 25(38): 5850-5861 [PMID: 31636477 DOI: 10.3748/wjg.v25.i38.5850] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
72 Calabrese E, Hanauer SB. Assessment of non-cirrhotic portal hypertension associated with thiopurine therapy in inflammatory bowel disease. J Crohns Colitis. 2011;5:48-53. [PMID: 21272804 DOI: 10.1016/j.crohns.2010.08.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
73 Cohen G, Cooper S, Sison EA, Annesley C, Bhuiyan M, Brown P. Allopurinol use during pediatric acute lymphoblastic leukemia maintenance therapy safely corrects skewed 6-mercaptopurine metabolism, improving inadequate myelosuppression and reducing gastrointestinal toxicity. Pediatr Blood Cancer 2020;67:e28360. [PMID: 32909665 DOI: 10.1002/pbc.28360] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
74 Coenen MJ, de Jong DJ, van Marrewijk CJ, Derijks LJ, Vermeulen SH, Wong DR, Klungel OH, Verbeek AL, Hooymans PM, Peters WH, te Morsche RH, Newman WG, Scheffer H, Guchelaar HJ, Franke B; TOPIC Recruitment Team. Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease. Gastroenterology 2015; 149: 907-17. e7. [PMID: 26072396 DOI: 10.1053/j.gastro.2015.06.002] [Cited by in Crossref: 109] [Cited by in F6Publishing: 94] [Article Influence: 15.6] [Reference Citation Analysis]
75 Citterio-quentin A, Long S, Salvi J, Moulsma M, Boulieu R. Determination of Inosine Triphosphate Pyrophosphatase in Red Blood Cells Using HPLC: An Improved Method. Therapeutic Drug Monitoring 2014;36:689-91. [DOI: 10.1097/ftd.0000000000000075] [Cited by in Crossref: 4] [Article Influence: 0.5] [Reference Citation Analysis]
76 Qiu Y, Chen BL, Mao R, Zhang SH, He Y, Zeng ZR, Chen MH. Endoscopy Assessment at 1-Year Identifies Long-Term Responders to Thiopurines Maintenance Therapy in Patients With Crohn's Disease. Medicine (Baltimore) 2015;94:e1204. [PMID: 26252278 DOI: 10.1097/MD.0000000000001204] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
77 Shi HY, Ng SC. The state of the art on treatment of Crohn's disease. J Gastroenterol. 2018;53:989-998. [PMID: 29980848 DOI: 10.1007/s00535-018-1479-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
78 Meijer B, Mulder CJJ, Bouma G, Ponsioen CY, van der Woude CJ, van der Meulen AE, Wintjens DSJ, Dijkstra G, Hoentjen F, Oldenburg B, van Bodegraven AA, de Boer NKH; Dutch Initiative on Crohn and Colitis (ICC) and Parelsnoer Institute. Methotrexate and Thioguanine Rescue Therapy for Conventional Thiopurine Failing Ulcerative Colitis Patients: A Multi-center Database Study on Tolerability and Effectiveness. Inflammatory Bowel Diseases 2018;24:1558-65. [DOI: 10.1093/ibd/izy047] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
79 Nissen LHC, Pierik M, Derikx LAAP, de Jong E, Kievit W, van den Heuvel TRA, van Rosendael AR, Plasmeijer EI, Dewint P, Verhoeven RHA, Overbeek LIH, Nagtegaal ID, Hoentjen F, van der Meulen–de Jong AE. Risk Factors and Clinical Outcomes in Patients with IBD with Melanoma: . Inflammatory Bowel Diseases 2017;23:2018-26. [DOI: 10.1097/mib.0000000000001191] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 2.4] [Reference Citation Analysis]
80 Pecher D, Dokupilová S, Zelinková Z, Peppelenbosch M, Lučeničová J, Mikušová V, Mikuš P. Analytical and Sample Preparation Protocol for Therapeutic Drug Monitoring of 12 Thiopurine Metabolites Related to Clinical Treatment of Inflammatory Bowel Disease. Molecules 2018;23:E1744. [PMID: 30018218 DOI: 10.3390/molecules23071744] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
81 van Asseldonk DP, Sanderson J, de Boer NK, Sparrow MP, Lémann M, Ansari A, Almer SH, Florin TH, Gearry RB, Mulder CJ. Difficulties and possibilities with thiopurine therapy in inflammatory bowel disease--proceedings of the first Thiopurine Task Force meeting. Dig Liver Dis. 2011;43:270-276. [PMID: 20934926 DOI: 10.1016/j.dld.2010.09.001] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 3.1] [Reference Citation Analysis]
82 van Gerven NM, Verwer BJ, Witte BI, van Hoek B, Coenraad MJ, van Erpecum KJ, Beuers U, van Buuren HR, de Man RA, Drenth JP, den Ouden JW, Verdonk RC, Koek GH, Brouwer JT, Guichelaar MM, Mulder CJ, van Nieuwkerk KM, Bouma G; Dutch Autoimmune Hepatitis Working Group. Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. J Hepatol. 2013;58:141-147. [PMID: 22989569 DOI: 10.1016/j.jhep.2012.09.009] [Cited by in Crossref: 116] [Cited by in F6Publishing: 102] [Article Influence: 11.6] [Reference Citation Analysis]
83 Gisbert JP, Barreiro-de Acosta M, Esteve M, García-Sánchez V, Gomollón F, Guardiola J, Hinojosa J, Martín Arranz MD, Minguez M, Taxonera C, Vera I. Physician Perspectives on Unresolved Issues in the Management of Ulcerative Colitis: The UC Horizons Project. Inflamm Bowel Dis 2016;22:583-98. [PMID: 26529561 DOI: 10.1097/MIB.0000000000000617] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
84 Schoultz I, Keita ÅV. Cellular and Molecular Therapeutic Targets in Inflammatory Bowel Disease-Focusing on Intestinal Barrier Function. Cells 2019;8:E193. [PMID: 30813280 DOI: 10.3390/cells8020193] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 17.0] [Reference Citation Analysis]
85 Crouwel F, Buiter HJC, de Boer NKH. There is still a place for optimised thiopurine therapy in IBD. Gut 2021;70:2207. [PMID: 33239341 DOI: 10.1136/gutjnl-2020-323481] [Reference Citation Analysis]
86 Lim SZ, Chua EW. Revisiting the Role of Thiopurines in Inflammatory Bowel Disease Through Pharmacogenomics and Use of Novel Methods for Therapeutic Drug Monitoring. Front Pharmacol. 2018;9:1107. [PMID: 30349479 DOI: 10.3389/fphar.2018.01107] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
87 Deben DS, van Adrichem AJ, Drent R, Puts S, Pelzer KEJM, van Bodegraven AA, Wong DR, Leers MPG. Rac1/pSTAT3 expression: A pharmacodynamic marker panel as a first step toward optimization of thiopurine therapy in inflammatory bowel disease patients. Cytometry A 2021. [PMID: 34595833 DOI: 10.1002/cyto.a.24506] [Reference Citation Analysis]
88 Nguyen ALH, Sparrow MP. Evolving Role of Thiopurines in Inflammatory Bowel Disease in the Era of Biologics and New Small Molecules. Dig Dis Sci 2021;66:3250-62. [PMID: 33073334 DOI: 10.1007/s10620-020-06662-z] [Reference Citation Analysis]
89 Triantafillidis JK, Merikas E, Georgopoulos F. Current and emerging drugs for the treatment of inflammatory bowel disease. Drug Des Devel Ther. 2011;5:185-210. [PMID: 21552489 DOI: 10.2147/dddt.s11290] [Cited by in Crossref: 137] [Cited by in F6Publishing: 76] [Article Influence: 12.5] [Reference Citation Analysis]
90 Fangbin Z, Xiang G, Liang D, Hui L, Xueding W, Baili C, Huichang B, Yinglian X, Peng C, Lizi Z. Prospective Evaluation of Pharmacogenomics and Metabolite Measurements upon Azathioprine Therapy in Inflammatory Bowel Disease: An Observational Study (Baltimore). Medicine. 2016;95:e3326. [PMID: 27082580 DOI: 10.1097/md.0000000000003326] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
91 Lee SD, Shivashankar R, Quirk D, Zhang H, Telliez JB, Andrews J, Marren A, Mukherjee A, Loftus EV Jr. Therapeutic Drug Monitoring for Current and Investigational Inflammatory Bowel Disease Treatments. J Clin Gastroenterol 2021;55:195-206. [PMID: 32740098 DOI: 10.1097/MCG.0000000000001396] [Reference Citation Analysis]
92 van Asseldonk DP, Jharap B, Kuik DJ, de Boer NK, Westerveld BD, Russel MG, Kubben FJ, van Bodegraven AA, Mulder CJ. Prolonged thioguanine therapy is well tolerated and safe in the treatment of ulcerative colitis. Dig Liver Dis. 2011;43:110-115. [PMID: 20739231 DOI: 10.1016/j.dld.2010.07.004] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
93 Meijer B, Seinen ML, Leijte NN, Mulder CJ, van Bodegraven AA, de Boer NK. Clinical Value of Mercaptopurine After Failing Azathioprine Therapy in Patients With Inflammatory Bowel Disease. Ther Drug Monit. 2016;38:463-470. [PMID: 27158876 DOI: 10.1097/ftd.0000000000000312] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
94 Qiu M, Huang S, Luo C, Wu Z, Liang B, Huang H, Ci Z, Zhang D, Han L, Lin J. Pharmacological and clinical application of heparin progress: An essential drug for modern medicine. Biomed Pharmacother 2021;139:111561. [PMID: 33848775 DOI: 10.1016/j.biopha.2021.111561] [Reference Citation Analysis]
95 Houwen JPA, Egberts ACG, de Boer A, van Maarseveen EM, Houwen RHJ, Lalmohamed A. Influence of allopurinol on thiopurine associated toxicity: A retrospective population-based cohort study. Br J Clin Pharmacol 2021;87:2333-40. [PMID: 33118191 DOI: 10.1111/bcp.14625] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
96 Taylor KM, Irving PM. Optimization of conventional therapy in patients with IBD. Nat Rev Gastroenterol Hepatol. 2011;8:646-656. [PMID: 21970871 DOI: 10.1038/nrgastro.2011.172] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 3.6] [Reference Citation Analysis]
97 Zakerska-banaszak O, Łykowska-szuber L, Walczak M, Żuraszek J, Zielińska A, Skrzypczak-zielińska M. Cytotoxicity of Thiopurine Drugs in Patients with Inflammatory Bowel Disease. Toxics 2022;10:151. [DOI: 10.3390/toxics10040151] [Reference Citation Analysis]
98 Stocco G, Cuzzoni E, Iudicibus SD, Favretto D, Malusà N, Martelossi S, Pozzi E, Lionetti P, Ventura A, Decorti G. Thiopurine metabolites variations during co-treatment with aminosalicylates for inflammatory bowel disease: Effect of N-acetyl transferase polymorphisms. World J Gastroenterol 2015; 21(12): 3571-3578 [PMID: 25834322 DOI: 10.3748/wjg.v21.i12.3571] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
99 Chavoushi SF, Jharap B, Friedrich P, Smid K, Peters GJ, Malingré M. Thiopurines with low-dose allopurinol (ThiLDA)-a prospective clinical one-way crossover trial. Eur J Clin Pharmacol 2019;75:1669-74. [PMID: 31587102 DOI: 10.1007/s00228-019-02760-8] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
100 Kreijne JE, Seinen ML, Wilhelm AJ, Bouma G, Mulder CJ, van Bodegraven AA, de Boer NK. Routinely Established Skewed Thiopurine Metabolism Leads to a Strikingly High Rate of Early Therapeutic Failure in Patients With Inflammatory Bowel Disease. Ther Drug Monit 2015;37:797-804. [PMID: 25853923 DOI: 10.1097/FTD.0000000000000213] [Cited by in Crossref: 19] [Cited by in F6Publishing: 5] [Article Influence: 3.2] [Reference Citation Analysis]
101 Larussa T, Suraci E, Lentini M, Nazionale I, Gallo L, Abenavoli L, Imeneo M, Costanzo FS, Cuda G, Luzza F. High prevalence of polymorphism and low activity of thiopurine methyltransferase in patients with inflammatory bowel disease. Eur J Intern Med. 2012;23:273-277. [PMID: 22385887 DOI: 10.1016/j.ejim.2011.12.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
102 Gilissen LP, Wong DR, Engels LG, Bierau J, Bakker JA, Paulussen AD, Romberg-Camps MJ, Stronkhorst A, Bus P, Bos LP. Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy. J Crohns Colitis. 2012;6:698-707. [PMID: 22398098 DOI: 10.1016/j.crohns.2011.12.003] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 5.0] [Reference Citation Analysis]
103 Musumba CO. Review article: the association between nodular regenerative hyperplasia, inflammatory bowel disease and thiopurine therapy. Aliment Pharmacol Ther 2013;38:1025-37. [PMID: 24099468 DOI: 10.1111/apt.12490] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
104 Wong DR, Coenen MJ, Vermeulen SH, Derijks LJ, van Marrewijk CJ, Klungel OH, Scheffer H, Franke B, Guchelaar HJ, de Jong DJ, Engels LG, Verbeek AL, Hooymans PM; TOPIC recruitment team. Early Assessment of Thiopurine Metabolites Identifies Patients at Risk of Thiopurine-induced Leukopenia in Inflammatory Bowel Disease. J Crohns Colitis. 2017;11:175-184. [PMID: 27402913 DOI: 10.1093/ecco-jcc/jjw130] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 5.7] [Reference Citation Analysis]
105 Tack GJ, Waayenberg P, de Boer NK. Beneficial pharmacological interaction between thiopurine and mesalazine—never change a winning team. J Crohns Colitis 2014;8:1743-4. [PMID: 25175784 DOI: 10.1016/j.crohns.2014.08.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
106 Kreijne JE, de Vries AC, de Veer RC, Bouma G, Dijkstra G, Voskuil MD, West R, van Moorsel SAW, de Jong DJ, de Boer NK, van der Woude CJ; initiative on Crohn and Colitis (ICC). Limited added value of laboratory monitoring in thiopurine maintenance monotherapy in inflammatory bowel disease patients. Aliment Pharmacol Ther 2020;51:1353-64. [PMID: 32342997 DOI: 10.1111/apt.15734] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
107 Goldberg R, Irving PM. Toxicity and response to thiopurines in patients with inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2015;9:891-900. [PMID: 25915575 DOI: 10.1586/17474124.2015.1039987] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
108 Kummen M, Schrumpf E, Boberg KM. Liver abnormalities in bowel diseases. Best Pract Res Clin Gastroenterol. 2013;27:531-542. [PMID: 24090940 DOI: 10.1016/j.bpg.2013.06.013] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
109 van Hoeve K, Vermeire S. Thiopurines in Pediatric Inflammatory Bowel Disease: Current and Future Place. Paediatr Drugs 2020;22:449-61. [PMID: 32797366 DOI: 10.1007/s40272-020-00411-5] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
110 Bakulin IG, Skalinskaya MI, Maev IV, Skazyvaeva EV, Zhuravleva MS, Gaikovaya LB, Bakulina NV, Ermakov AI, Alekseenko ES, Ivanova KN, Solovev MV. Pharmacotherapy of inflammatory bowel diseases: efficacy performance and safety management. Terapevticheskii arkhiv 2021;93:841-52. [DOI: 10.26442/00403660.2021.08.200982] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
111 Biancone L, Annese V, Ardizzone S, Armuzzi A, Calabrese E, Caprioli F, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D’incà R, Frieri G, Fries W, Gionchetti P, Kohn A, Latella G, Milla M, Orlando A, Papi C, Petruzziello C, Riegler G, Rizzello F, Saibeni S, Scribano ML, Vecchi M, Vernia P, Meucci G, Aratari A, Bossa F, Cappello M, Cassinotti A, Chiriatti A, Fiorino G, Formica V, Guidi L, Losco A, Mocciaro F, Onali S, Pastorelli L, Pica R, Principi M, Renna S, Ricci C, Rispo A, Rogai F, Sarmati L, Scaldaferri F, Spina L, Tambasco R, Testa A, Viscido A. Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease 2017;49:338-58. [DOI: 10.1016/j.dld.2017.01.141] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
112 Bradford K, Shih DQ. Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease. World J Gastroenterol 2011; 17(37): 4166-4173 [PMID: 22072847 DOI: 10.3748/wjg.v17.i37.4166] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 43] [Article Influence: 3.7] [Reference Citation Analysis]
113 Chen L, Gao Y, Zhang Z, Sun M, Yang W, Liu Z, Jiang X. Umbilical cord blood mononuclear cell therapy induces clinical remission of steroid-dependent or -resistant ulcerative colitis patients. Oncotarget 2018;9:15027-35. [PMID: 29599923 DOI: 10.18632/oncotarget.24541] [Reference Citation Analysis]
114 Axelrad JE, Roy A, Lawlor G, Korelitz B, Lichtiger S. Thiopurines and inflammatory bowel disease: Current evidence and a historical perspective. World J Gastroenterol 2016; 22(46): 10103-10117 [PMID: 28028358 DOI: 10.3748/wjg.v22.i46.10103] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 23] [Article Influence: 4.5] [Reference Citation Analysis]
115 Tack GJ, van Asseldonk DP, van Wanrooij RL, van Bodegraven AA, Mulder CJ. Tioguanine in the treatment of refractory coeliac disease--a single centre experience. Aliment Pharmacol Ther 2012;36:274-81. [PMID: 22646133 DOI: 10.1111/j.1365-2036.2012.05154.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
116 Shamberg L, Vaziri H. Hepatotoxicity of Inflammatory Bowel Disease Medications. Journal of Clinical Gastroenterology 2018;52:674-84. [DOI: 10.1097/mcg.0000000000001084] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
117 Uchiyama K, Takagi T, Iwamoto Y, Kondo N, Okayama T, Yoshida N, Kamada K, Katada K, Handa O, Ishikawa T, Yasuda H, Sakagami J, Konishi H, Yagi N, Naito Y, Itoh Y. New genetic biomarkers predicting azathioprine blood concentrations in combination therapy with 5-aminosalicylic acid. PLoS One 2014;9:e95080. [PMID: 24762746 DOI: 10.1371/journal.pone.0095080] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
118 van Asseldonk DP, Jharap B, Verheij J, den Hartog G, Westerveld DB, Becx MC, Russel MG, Engels LG, de Jong DJ, Witte BI. The Prevalence of Nodular Regenerative Hyperplasia in Inflammatory Bowel Disease Patients Treated with Thioguanine Is Not Associated with Clinically Significant Liver Disease. Inflamm Bowel Dis. 2016;22:2112-2120. [PMID: 27482972 DOI: 10.1097/mib.0000000000000869] [Cited by in Crossref: 27] [Cited by in F6Publishing: 12] [Article Influence: 6.8] [Reference Citation Analysis]
119 van de Ven SEM, Derikx LAAP, Nagtegaal ID, van Herpen CM, Takes RP, Melchers WJG, Pierik M, van den Heuvel T, Verhoeven RHA, Hoentjen F, Nissen LHC. Laryngeal Carcinoma in Patients With Inflammatory Bowel Disease: Clinical Outcomes and Risk Factors. Inflamm Bowel Dis 2020;26:1060-7. [PMID: 31559415 DOI: 10.1093/ibd/izz210] [Reference Citation Analysis]
120 Moran GW, Dubeau MF, Kaplan GG, Yang H, Eksteen B, Ghosh S, Panaccione R. Clinical predictors of thiopurine-related adverse events in Crohn's disease. World J Gastroenterol 2015; 21(25): 7795-7804 [PMID: 26167079 DOI: 10.3748/wjg.v21.i25.7795] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 14] [Article Influence: 3.1] [Reference Citation Analysis]
121 Wildenberg ME, Levin AD, Ceroni A, Guo Z, Koelink PJ, Hakvoort TBM, Westera L, Bloemendaal FM, Brandse JF, Simmons A, D'Haens GR, Ebner D, van den Brink GR. Benzimidazoles Promote Anti-TNF Mediated Induction of Regulatory Macrophages and Enhance Therapeutic Efficacy in a Murine Model. J Crohns Colitis 2017;11:1480-90. [PMID: 28961920 DOI: 10.1093/ecco-jcc/jjx104] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
122 Costantino G, Furfaro F, Belvedere A, Alibrandi A, Fries W. Thiopurine treatment in inflammatory bowel disease: response predictors, safety, and withdrawal in follow-up. J Crohns Colitis. 2012;6:588-596. [PMID: 22398045 DOI: 10.1016/j.crohns.2011.11.007] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 2.7] [Reference Citation Analysis]
123 Pecher D, Zelinkova Z, Lucenicova J, Peppelenbosch M, Dokupilova S, Mikusova V, Mikus P. Porous graphitic carbon based chromatography hyphenated with mass spectrometry: A new strategy for profiling thiopurine nucleotides in patients with inflammatory bowel diseases. Anal Chim Acta 2020;1137:64-73. [PMID: 33153610 DOI: 10.1016/j.aca.2020.08.064] [Reference Citation Analysis]
124 Kverka M, Rossmann P, Tlaskalova-Hogenova H, Klimesova K, Jharap B, de Boer NK, Vos RM, van Bodegraven AA, Lukas M, Mulder CJ. Safety and efficacy of the immunosuppressive agent 6-tioguanine in murine model of acute and chronic colitis. BMC Gastroenterol. 2011;11:47. [PMID: 21545711 DOI: 10.1186/1471-230x-11-47] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
125 Haglund S, Vikingsson S, Almer S, Söderman J. Combination treatment with 6-mercaptopurine and allopurinol in HepG2 and HEK293 cells - Effects on gene expression levels and thiopurine metabolism. PLoS One 2017;12:e0173825. [PMID: 28278299 DOI: 10.1371/journal.pone.0173825] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
126 van Asseldonk DP, Seinen ML, de Boer NK, van Bodegraven AA, Mulder CJ. Hepatotoxicity associated with 6-methyl mercaptopurine formation during azathioprine and 6-mercaptopurine therapy does not occur on the short-term during 6-thioguanine therapy in IBD treatment. J Crohns Colitis. 2012;6:95-101. [PMID: 22261533 DOI: 10.1016/j.crohns.2011.07.009] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
127 Zhou HY, Guo B, Lufumpa E, Li XM, Chen LH, Meng X, Li BZ. Comparative of the Effectiveness and Safety of Biological Agents, Tofacitinib, and Fecal Microbiota Transplantation in Ulcerative Colitis: Systematic Review and Network Meta-Analysis. Immunol Invest 2021;50:323-37. [PMID: 32009472 DOI: 10.1080/08820139.2020.1714650] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]